Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Drug Manufacturers - Specialty & Generic

Healthcare
$29.71 -1.60%

-$0.31 today

Market cap
$1.27B
Beta
0.90
P/E (TTM)
10.9
EPS (TTM)
$1.75
52W Low $16.65High $31.26

Volume 0.53M

Average 0.59M

AMPH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $6.42M fell 74.6% year over year, behind the -44.1% change in trailing-twelve-month net income. Sequentially, it fell 73.7% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Net income amounted to 13.6% of revenue in FY2025, down 8.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of $143.03M (+45.8%) for the fiscal year ending Dec 2026, a step up from the -38.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.42M-73.7% QoQ
Last fiscal yearDec 2025
$98.09M-38.5% YoY
LTMMar 2026
$79.23M-44.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.6%-13.3%+61.3 pp
1 year-38.5%+45.8%+84.3 pp
3-year CAGR+2.4%+20.5%+18.1 pp
5-year CAGR+10.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
98.09M USD
Year-over-year change
-38.5%
4-year CAGR
+11.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AMPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.1% is the 4th highest of 8, against a peer median of -52.4%.
  • Net income amounts to 11.0% of revenue for AMPH, versus a peer median of 6.9%.
AMPH Competitors
Net Income for AMPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹27.72B INR-52.4%+0.0%8.4%
BHCBausch Health Companies Inc.LTM Jun 2026$1.1B USD-2132.0%—10.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$709M USD+537.7%—4.1%
VTRSViatris Inc.LTM Jun 2026$410.7M USD-88.2%—2.8%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$215.32M USD+320.2%—6.9%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$79.23M USD-44.1%+2.4%11.0%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$74.95M USD+70.7%—9.4%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$1.48M USD-67.8%-20.1%1.7%
Peer median (excluding AMPH) —-52.4%-10.0%6.9%

Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income63.3M91.39M137.55M159.52M98.09M
Depreciation & Amortization26.75M28.74M41.78M57.21M63.2M
Deferred Income Tax4.21M(15.75M)(13.74M)(17.87M)27.63M
Stock-Based Compensation18.69M17.86M20.24M24.37M27.28M
Change in Working Capital(1.92M)(32.18M)(24.21M)(14.55M)(65.97M)
Accounts Receivables(14.92M)(10.13M)(26.09M)(21.67M)(6.37M)
Inventory1.26M(11.75M)(1.72M)(48.8M)(21.06M)
Accounts Payables3.02M(736K)13.24M63.56M(4.56M)
Other Working Capital8.72M(9.56M)(9.64M)(7.64M)(33.98M)
Other Non-Cash Items(13.03M)(878K)21.89M4.71M5.89M
Operating Cash Flow97.99M89.18M183.5M213.39M156.12M
Capital Expenditures(27.46M)(24.03M)(38.17M)(41.04M)(34.88M)
Acquisitions (Net)0421K(506.41M)(129M)0
Purchases of Investments(17.38M)(35.76M)(144.56M)(76.79M)(119.13M)
Sales of Investments18.77M27.97M38.62M126.02M90.29M
Other Investing Activities(2.61M)(1.37M)1.39M(4.12M)(6.61M)
Investing Cash Flow(28.67M)(32.78M)(649.12M)(124.93M)(70.33M)
Debt Repayment32.1M(1.78M)526.34M10.17M5.99M
Common Stock Issued00002.86M
Common Stock Repurchased(28.87M)(39.91M)(58.14M)(85.46M)(75.59M)
Dividends Paid00000
Other Financing Activities(40.24M)15.25M(14.11M)(5.67M)(687K)
Financing Cash Flow(37.02M)(26.44M)454.09M(80.95M)(67.43M)
Effect of Forex Changes(223K)(220K)(282K)(190K)210K
Net Change in Cash32.08M29.75M(11.8M)7.31M18.57M
Free Cash Flow70.54M65.15M145.34M172.35M121.23M

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

Intrinsic Alpha fair value

Locked

Current Price

$29.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.